Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 3/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5400603 | 0.86 | SLC16A1 (0.52) | PDE1APDE1BPDE1C | |
| SCHEMBL5407560 | 0.83 | SLC16A1 (0.45) | — | |
| SCHEMBL5413282 | 0.83 | PDE1A (0.42) | PDE1APDE1BPDE1CPDE2ATDP1 | |
| SCHEMBL5407603 | 0.82 | PDE1A (0.40) | PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL5408098 | 0.82 | PDE1A (0.37) | PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL5400103 | 0.82 | PDE1A (0.42) | PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL5399832 | 0.82 | PDE5A (0.37) | PDE1APDE1BPDE1C | |
| SCHEMBL5399970 | 0.82 | PDE5A (0.37) | PDE1APDE1BPDE1C | |
| SCHEMBL5407784 | 0.81 | — | — | |
| SCHEMBL5393985 | 0.81 | PDE1A (0.40) | PDE1APDE1BPDE1CPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1573000-B1 | CRYSTAL STRUCTURE OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | PDE1A 4056/4885PDE1B 4206/4885PDE1C 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.